Avoro Capital Advisors LLC Reports New 6.27% Stake in Damora Therapeutics, Inc. (GLTO)

On May 15, 2026, Avoro Capital Advisors LLC and Dr. Behzad Aghazadeh filed a Schedule 13G disclosing a new 6.27% stake in Damora Therapeutics, Inc. (ticker: GLTO). The reporting persons beneficially own 3,783,000 shares of Common Stock as of the event date on March 31, 2026. Avoro Capital Advisors LLC provides investment management services to the Avoro Life Sciences Fund LLC, while Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro. The filing indicates that the shares were acquired in the ordinary course of business for investment purposes and not with the intent to influence or change the control of the issuer. The percentage ownership is based on 60,303,212 shares outstanding as reported in the company's 2025 Annual Report. Both reporting persons share sole voting and dispositive power over the reported shares. This filing marks an increase from a previously reported 0.0% position, establishing Avoro as a significant institutional shareholder.